Observational studyRheumatology (Oxford, England)2026
Acute parvovirus B19-associated inflammatory musculoskeletal disease: clinical phenotypes and remission trajectories from the GIRRCS network.
Observational study in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe clinical phenotype, selected imaging findings and remission trajectories in adults with acute parvovirus B19-associated inflammatory musculoskeletal disease referred for rheumatological assessment.
methodsThis was a non-interventional multicentre observational study in GIRRCS rheumatology units. Adults with new-onset inflammatory musculoskeletal manifestations, positive anti-parvovirus B19 IgM and symptom onset within 4 weeks were enrolled. Clinical, laboratory and clinically indicated imaging data were collected. Time to first documented clinical remission was defined as the interval from symptom onset to the first rheumatologist-confirmed assessment showing resolution of inflammatory musculoskeletal manifestations. Patients requiring disease-modifying escalation were analysed separately.
resultsTwenty-four adults were enrolled; 18 were women (75.0%) and mean age was 44.4 ± 14.8 years. Clinical involvement was polyarticular in 14 patients (58.3%) and oligoarticular in 10 (41.7%); enthesitis occurred in 4 (16.7%) and dactylitis was absent. Inflammatory markers were modestly elevated, and most patients with complete autoantibody data were seronegative. Imaging was performed selectively and documented inflammatory abnormalities in clinically indicated examinations. Follow-up data were available for 21 patients, of whom 20 (95.2%) achieved clinical remission without DMARD escalation; median documented remission timing was 21 days (IQR 10-60; range 7-135). One patient required biologic escalation for persistent inflammatory disease. Exploratory regression analyses did not identify robust associations with documented remission timing.
conclusionAcute parvovirus B19-associated inflammatory musculoskeletal disease may mimic inflammatory rheumatic disease in adults referred for rheumatological assessment. Most patients achieved remission without disease-modifying escalation, although remission timing varied and one patient required biologic therapy for persistent inflammatory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.